Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID GREGORY BRABHAM

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1447424007
CMS profile
201301
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$31,199.96

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID GREGORY BRABHAM

NPI 1447424007 · CMS profile ID 201301

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447424007?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID GREGORY BRABHAM, NPI 1447424007, CMS profile ID 201301. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447424007?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID GREGORY BRABHAM, NPI 1447424007, CMS profile ID 201301. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447424007?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID GREGORY BRABHAM, NPI 1447424007, CMS profile ID 201301, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447424007?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $31,199.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–73 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $8.4205/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944504039 CMS
Abbott Laboratories $13.8305/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920497179 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,850.0005/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887768257 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $122.7904/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887355579 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $738.0004/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887768255 CMS
ABIOMED $0.8704/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059727 CMS
ABIOMED $1.6804/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059751 CMS
Boston Scientific Corporation $31.4604/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916812807 CMS
ABIOMED $1.6804/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059734 CMS
Lilly USA, LLC $1,320.0004/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917992317 CMS
ABIOMED $3.4203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059686 CMS
Abbott Laboratories $22.7603/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910328209 CMS
Abbott Laboratories $33.6403/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920497195 CMS
CORDIS US CORP. $2,250.0003/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965257889 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,425.0003/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887768263 CMS
BIOTRONIK INC. $12.3102/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949035549 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $115.4302/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887768261 CMS
Abbott Laboratories $26.1402/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920497187 CMS
Abbott Laboratories $11.7902/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920472445 CMS
ABIOMED $1.0201/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059637 CMS
ABIOMED $0.8701/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059655 CMS
ABIOMED $5.6101/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942059647 CMS
Abbott Laboratories $34.9601/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920497203 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,657.63 65
PY2020 $20,360.83 43
PY2021 $15,678.92 49
PY2022 $31,199.96 73
PY2023 $16,242.55 65
PY2024 $7,821.88 45
PY2025 $16,006.49 39

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,621,081.00 190
PY2024 Recipient $42,780.00 1
PY2024 Principal investigator $1,476,901.49 130
PY2023 Recipient $62.72 1
PY2023 Principal investigator $1,169,396.66 192
PY2022 Recipient $50.00 1
PY2022 Principal investigator $1,926,899.82 292
PY2021 Principal investigator $2,386,431.18 372
PY2020 Principal investigator $2,430,537.63 86
PY2019 Principal investigator $326,440.00 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

190 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670298
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/17/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996070
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/15/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670486
Principal investigator 1 Boehringer Ingelheim International GmbH $2,012.00 12/15/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670488
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/15/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670490
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670292
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670464
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670466
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670468
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670470
Principal investigator 1 Boehringer Ingelheim International GmbH $2,835.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670472
Principal investigator 1 Boehringer Ingelheim International GmbH $317.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670474
Principal investigator 1 Boehringer Ingelheim International GmbH $1,916.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670476
Principal investigator 1 Boehringer Ingelheim International GmbH $2,835.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670478
Principal investigator 1 Boehringer Ingelheim International GmbH $2,801.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670480
Principal investigator 1 Boehringer Ingelheim International GmbH $1,916.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670482
Principal investigator 1 Boehringer Ingelheim International GmbH $2,835.00 12/12/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670484
Principal investigator 1 Janssen Research & Development, LLC $2,819.00 12/12/2025 Non-covered Recipient Entity
Clinicaltex Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274778
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/03/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996056
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670460
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670462
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996068
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,077.90 11/24/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190306647
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,893.00 11/24/2025 Non-covered Recipient Entity
CCA - RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313151
Principal investigator 1 Boehringer Ingelheim International GmbH $2,660.00 11/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670288
Principal investigator 1 Boehringer Ingelheim International GmbH $1,995.00 11/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670290
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670296
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 11/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670454
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 11/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670456
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 11/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670458
Principal investigator 1 Janssen Research & Development, LLC $3,822.00 11/19/2025 Non-covered Recipient Entity
Clinicaltex Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274820
Principal investigator 1 Janssen Research & Development, LLC $7,027.00 11/07/2025 Non-covered Recipient Entity
Clinicaltex Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274873
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,622.98 11/06/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420223
Principal investigator 1 Janssen Research & Development, LLC $814.00 11/03/2025 Non-covered Recipient Entity
Clinicaltex Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274714
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670450
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670452
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670294
Principal investigator 1 Amgen Inc. $53,109.25 10/24/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC DBA PHARMATEX RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246640399
Principal investigator 1 Boehringer Ingelheim International GmbH $3,271.00 10/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670284
Principal investigator 1 Boehringer Ingelheim International GmbH $2,769.00 10/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670286
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 10/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670446
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 10/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670448
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,952.32 10/14/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190306645
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/09/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996054
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $481.77 10/08/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420217
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 10/06/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996052
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,155.80 10/06/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190306643
Principal investigator 1 Boehringer Ingelheim International GmbH $3,271.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670276
Principal investigator 1 Boehringer Ingelheim International GmbH $2,769.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670278
Principal investigator 1 Boehringer Ingelheim International GmbH $1,995.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670280
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670282
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670440
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670442
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 10/02/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670444
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670436
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670438
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 09/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996066
Principal investigator 1 Amgen Inc. $5,634.00 09/23/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC DBA PHARMATEX RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640397
Principal investigator 1 Janssen Research & Development, LLC $58,151.00 09/19/2025 Non-covered Recipient Entity
Clinicaltex Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274679
Principal investigator 1 Novartis Pharmaceuticals Corporation $78,940.61 09/15/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190309622
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $887.49 09/08/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $172.40 09/03/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 09/03/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,308.00 09/03/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522793
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670424
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670426
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 08/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670432
Principal investigator 1 Boehringer Ingelheim International GmbH $281.00 08/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670434
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 08/18/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996050
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 08/13/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996064
Principal investigator 1 Alnylam Pharmaceuticals Inc. $104.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,385.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $56.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $218.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $702.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,088.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $80.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $124.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $234.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $821.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $62.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $160.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $174.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $138.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,138.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $56.00 08/07/2025 Non-covered Recipient Entity
ClinicalTex Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215522829
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,741.75 08/05/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420233
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670420
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670422
Principal investigator 1 Amgen Inc. $5,540.88 07/31/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246646505
Principal investigator 1 Boehringer Ingelheim International GmbH $48.60 07/29/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670270
Principal investigator 1 Boehringer Ingelheim International GmbH $5.40 07/29/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670272
Principal investigator 1 Amgen Inc. $1,576.83 07/28/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246646501
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 07/28/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670274
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,162.32 07/28/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190309770
Principal investigator 1 Novartis Pharmaceuticals Corporation $454.28 07/28/2025 Non-covered Recipient Entity
CCA - RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313153
Principal investigator 1 Boehringer Ingelheim International GmbH $2,537.00 07/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670410
Principal investigator 1 Boehringer Ingelheim International GmbH $281.00 07/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670412
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 07/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670414
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 07/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670416
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 07/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670418
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,000.00 07/15/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190303581
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,020.77 07/09/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420225
Principal investigator 1 Novartis Pharmaceuticals Corporation $51,405.26 07/02/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309626
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 07/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670268
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670428
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670430
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,000.00 07/01/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190303583
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670408
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 06/20/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670392
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,585.20 06/16/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190309776
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,020.32 06/12/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190309774
Principal investigator 1 Amgen Inc. $18,487.33 06/08/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246646508
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $10,780.00 06/04/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420227
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,280.00 06/04/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
Confirmation Study #22563 No dispute reported 06/30/2026 1225420243
Principal investigator 1 Boehringer Ingelheim International GmbH $1,420.00 06/04/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670382
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 06/04/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670384
Principal investigator 1 Boehringer Ingelheim International GmbH $2,537.00 06/04/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670386
Principal investigator 1 Boehringer Ingelheim International GmbH $2,537.00 06/04/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670388
Principal investigator 1 Boehringer Ingelheim International GmbH $1,931.00 06/04/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670390
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $833.49 06/02/2025 Non-covered Recipient Entity
Clinicaltex Research, Llc
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225420211
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670378
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670380
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 05/28/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996060
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670262
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 05/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670264
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220670266
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 05/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670402
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 05/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670404
Principal investigator 1 Boehringer Ingelheim International GmbH $11.28 05/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670406
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 05/08/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996048
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670374
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670376
Principal investigator 1 Boehringer Ingelheim International GmbH $3,352.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670358
Principal investigator 1 Boehringer Ingelheim International GmbH $3,352.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670360
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670362
Principal investigator 1 Boehringer Ingelheim International GmbH $2,468.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670364
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670366
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670368
Principal investigator 1 Boehringer Ingelheim International GmbH $1,931.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670370
Principal investigator 1 Boehringer Ingelheim International GmbH $2,720.00 04/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670372
Principal investigator 1 Boehringer Ingelheim International GmbH $479.52 04/23/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670394
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/23/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670396
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 04/23/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670398
Principal investigator 1 Boehringer Ingelheim International GmbH $4.65 04/23/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670400
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 04/08/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996062
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670354
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670356
Principal investigator 1 AstraZeneca Pharmaceuticals LP $166.70 03/26/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC
A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1185542986
Principal investigator 1 Boehringer Ingelheim International GmbH $53.00 03/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670336
Principal investigator 1 Boehringer Ingelheim International GmbH $53.00 03/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670338
Principal investigator 1 Boehringer Ingelheim International GmbH $1,420.00 03/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670340
Principal investigator 1 Boehringer Ingelheim International GmbH $1,931.00 03/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670342
Principal investigator 1 Boehringer Ingelheim International GmbH $2,720.00 03/19/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670344
Principal investigator 1 Janssen Research & Development, LLC $4,667.00 03/03/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346517
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670330
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670332
Principal investigator 1 Boehringer Ingelheim International GmbH $1,420.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670312
Principal investigator 1 Boehringer Ingelheim International GmbH $1,420.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670314
Principal investigator 1 Boehringer Ingelheim International GmbH $3,352.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670316
Principal investigator 1 Boehringer Ingelheim International GmbH $3,352.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670318
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670320
Principal investigator 1 Boehringer Ingelheim International GmbH $2,537.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670322
Principal investigator 1 Boehringer Ingelheim International GmbH $2,720.00 02/25/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670324
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 02/10/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220996058
Principal investigator 1 Novartis Pharmaceuticals Corporation $91,629.32 02/04/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190303577
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,136.78 02/04/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190303579
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670326
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670328
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,678.00 01/31/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 1185542988
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670334
Principal investigator 1 Novartis Pharmaceuticals Corporation $85,200.10 01/30/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190303575
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,930.61 01/28/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190309772
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 01/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670346
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 01/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670348
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 01/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670350
Principal investigator 1 Boehringer Ingelheim International GmbH $9.40 01/27/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670352
Principal investigator 1 Eli Lilly and Company $4,012.63 01/27/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC DBA PHARMATEX RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187877929
Principal investigator 1 Novartis Pharmaceuticals Corporation $291,856.89 01/27/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190309620
Principal investigator 1 Novartis Pharmaceuticals Corporation $197,870.35 01/23/2025 Non-covered Recipient Entity
PHARMATEX RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309624
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 01/22/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670300
Principal investigator 1 Boehringer Ingelheim International GmbH $1,420.00 01/22/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670302
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 01/22/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670304
Principal investigator 1 Boehringer Ingelheim International GmbH $2,537.00 01/22/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670306
Principal investigator 1 Janssen Research & Development, LLC $16,780.00 01/22/2025 Non-covered Recipient Entity
Clinicaltex Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274812
Principal investigator 1 Eli Lilly and Company $192,025.00 01/07/2025 Non-covered Recipient Entity
CLINICALTEX RESEARCH LLC DBA PHARMATEX RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878215
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670308
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Pharmatex Research
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220670310